Our proprietary technology is based on the efficient use of novel biocatalytic cascades. We have designed and engineered these pathways to produce activated sugars by magnitude of orders cheaper than the current production costs. Building on that, we are engineering biocatalysts to produce human milk oligosaccharides and tailor the glycosylation of therapeutic proteins.